FR3096579B1 - composition pour la protection et la reparation de la barriere hematoencephalique (BHE) - Google Patents

composition pour la protection et la reparation de la barriere hematoencephalique (BHE) Download PDF

Info

Publication number
FR3096579B1
FR3096579B1 FR1905566A FR1905566A FR3096579B1 FR 3096579 B1 FR3096579 B1 FR 3096579B1 FR 1905566 A FR1905566 A FR 1905566A FR 1905566 A FR1905566 A FR 1905566A FR 3096579 B1 FR3096579 B1 FR 3096579B1
Authority
FR
France
Prior art keywords
repair
protection
composition
bbb
hematoencephalic barrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1905566A
Other languages
English (en)
Other versions
FR3096579A1 (fr
Inventor
Myriam Bernaudin
Omar Touzani
Jérôme Toutain
Yacine Khelif
Denis Barritault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Caen Normandie
Organes Tissus Regeneration Reparation Remplacement SAS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Caen Normandie
OTR3 SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1905566A priority Critical patent/FR3096579B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Caen Normandie, OTR3 SAS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to KR1020217042420A priority patent/KR20220042310A/ko
Priority to AU2020284406A priority patent/AU2020284406A1/en
Priority to JP2021570515A priority patent/JP7578621B2/ja
Priority to CN202080047142.7A priority patent/CN114206354B/zh
Priority to CA3141923A priority patent/CA3141923A1/fr
Priority to EP20721621.9A priority patent/EP3976060A1/fr
Priority to PCT/EP2020/062081 priority patent/WO2020239356A1/fr
Priority to BR112021023737A priority patent/BR112021023737A2/pt
Priority to US17/595,818 priority patent/US20220152089A1/en
Publication of FR3096579A1 publication Critical patent/FR3096579A1/fr
Application granted granted Critical
Publication of FR3096579B1 publication Critical patent/FR3096579B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à une composition pharmaceutique pour son application comme médicament, en particulier pour son utilisation pour la protection de la barrière hématoencéphalique et/ou la réparation et/ou la restauration de la barrière hématoencéphalique. La présente invention trouve une application notamment dans les domaines thérapeutique, pharmaceutiques et vétérinaires. Figure abrégé [Fig. 3]
FR1905566A 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE) Active FR3096579B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1905566A FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
BR112021023737A BR112021023737A2 (pt) 2019-05-27 2020-04-30 Composição farmacêutica e uso
JP2021570515A JP7578621B2 (ja) 2019-05-27 2020-04-30 血液脳関門（ｂｂｂ）の保護及び修復のための組成物
CN202080047142.7A CN114206354B (zh) 2019-05-27 2020-04-30 用于保护和修复血脑屏障(bbb)的组合物
CA3141923A CA3141923A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)
EP20721621.9A EP3976060A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)
KR1020217042420A KR20220042310A (ko) 2019-05-27 2020-04-30 혈액-뇌 장벽(ｂｂｂ)의 보호 및 복구용 조성물
AU2020284406A AU2020284406A1 (en) 2019-05-27 2020-04-30 Composition for the protection and repair of the blood brain barrier
US17/595,818 US20220152089A1 (en) 2019-05-27 2020-04-30 Composition for the protection and repair of the blood brain barrier
PCT/EP2020/062081 WO2020239356A1 (fr) 2019-05-27 2020-04-30 Composition pour la protection et la reparation de la barriere hematoencephalique (bhe)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1905566 2019-05-27
FR1905566A FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)

Publications (2)

Publication Number Publication Date
FR3096579A1 FR3096579A1 (fr) 2020-12-04
FR3096579B1 true FR3096579B1 (fr) 2023-05-05

Family

ID=68138337

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1905566A Active FR3096579B1 (fr) 2019-05-27 2019-05-27 composition pour la protection et la reparation de la barriere hematoencephalique (BHE)

Country Status (10)

Country Link
US (1) US20220152089A1 (fr)
EP (1) EP3976060A1 (fr)
JP (1) JP7578621B2 (fr)
KR (1) KR20220042310A (fr)
CN (1) CN114206354B (fr)
AU (1) AU2020284406A1 (fr)
BR (1) BR112021023737A2 (fr)
CA (1) CA3141923A1 (fr)
FR (1) FR3096579B1 (fr)
WO (1) WO2020239356A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024119112A1 (fr) * 2022-12-01 2024-06-06 Stream Biomedical, Inc. Utilisation de perlécan et de fragments de celle-ci pour traiter une rupture de la barrière hémato-encéphalique
EP4620477A1 (fr) * 2024-03-18 2025-09-24 Organes Tissus Régénération Réparation Remplacement Biopolymères synthétiques d'héparane sulfate pour le traitement des accidents vasculaires cérébraux ischémiques

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439450A (en) * 1983-06-30 1984-03-27 The Upjohn Manufacturing Company M Treatment of the blood-brain barrier with ibuprofen
DE4021066A1 (de) * 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
US6573251B2 (en) * 1994-03-30 2003-06-03 Denis Barritault Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
FR2718025B1 (fr) * 1994-03-30 1996-06-21 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement des lésions du système nerveux.
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
EP1471870B1 (fr) * 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Utilisation de conjugues de lipides dans le traitement de maladies
FR2832708B1 (fr) * 2001-11-29 2004-02-13 Organes Tissus Regeneration Re Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires
CA2543530C (fr) 2003-10-28 2014-02-04 Denis Barritault Utilisation de polymeres biocompatibles pour la preparation d'une composition ou d'un dispositif medical
US20090062208A1 (en) 2007-02-06 2009-03-05 Mochly-Rosen Daria D Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor
US8343942B2 (en) * 2008-04-04 2013-01-01 University Of Utah Research Foundation Methods for treating interstitial cystitis
CN101632728B (zh) 2008-07-21 2013-08-07 河北以岭医药研究院有限公司 一种中药组合物在制备保护血脑屏障的药物中的应用
JP5648637B2 (ja) * 2009-08-10 2015-01-07 国立大学法人 長崎大学 血液脳関門障害改善剤
US20140256820A1 (en) * 2010-12-13 2014-09-11 Fukuoka University Therapeutic agent for blood-brain barrier disruption syndrome
WO2015184231A2 (fr) * 2014-05-30 2015-12-03 Kolltan Pharmaceuticals, Inc. Régulateurs de la kinase du lymphome anaplasique et leurs utilisations
EP3097928A1 (fr) * 2015-05-28 2016-11-30 Organes Tissus Régénération Réparation Remplacement Composition pour le traitement des lesions cerebrales
EP3097922A1 (fr) * 2015-05-28 2016-11-30 Denis Barritault Composition pour le traitement des lesions tissulaires
CN105148276B (zh) 2015-09-22 2018-11-20 深圳市第二人民医院 抑制Claudin-5降解阻止缺血性血脑屏障损伤的保护剂
JP7106340B2 (ja) 2017-05-12 2022-07-26 花王株式会社 血液脳関門保護剤

Also Published As

Publication number Publication date
KR20220042310A (ko) 2022-04-05
US20220152089A1 (en) 2022-05-19
CN114206354A (zh) 2022-03-18
JP2022534278A (ja) 2022-07-28
CN114206354B (zh) 2023-12-29
AU2020284406A1 (en) 2022-01-06
BR112021023737A2 (pt) 2022-02-01
CA3141923A1 (fr) 2020-12-03
WO2020239356A1 (fr) 2020-12-03
EP3976060A1 (fr) 2022-04-06
FR3096579A1 (fr) 2020-12-04
JP7578621B2 (ja) 2024-11-06

Similar Documents

Publication Publication Date Title
Gomes et al. Chlorhexidine in endodontics
Victorino et al. The effects of chlorhexidine and ethanol on push-out bond strength of fiber posts
CA3156676A1 (fr) Micro-aiguilles a base de fibroine de soie et leurs utilisations
Sabatini et al. Matrix metalloproteinase inhibitory properties of benzalkonium chloride stabilizes adhesive interfaces
Neelakantan et al. The shear bond strength of resin-based composite to white mineral trioxide aggregate
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
MA37809B1 (fr) Administration de médicament biodégradable pour compositions hydrophobes
EP1226109A4 (fr) Composes d'acide phenylamine carboxylique et compositions permettant de distribuer des agents actifs
BR0011433B1 (pt) Compostos de imidazoquinolinas substituídas com sulfonamida e sulfamida e composição farmaceutica cotendo os mesmos
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
Shafiei et al. Adhesion performance of a universal adhesive in the root canal: Effect of etch-and-rinse vs. self-etch mode
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
Wang et al. Effect of 2% chlorhexidine digluconate on bond strength of a glass‐fibre post to root dentine
Shafiei et al. Effect of carbodiimide on bonding durability of adhesive-cemented fiber posts in root canals
FR3096579B1 (fr) composition pour la protection et la reparation de la barriere hematoencephalique (BHE)
PE20110162A1 (es) Yoduro de povidona, un nuevo conservante alternativo para composiciones oftalmicas
PY0401585A (es) Formulaciones farmaceuticas liquidas de palonosetron
BR9808427A (pt) Produto, processo de preparação e utilização do mesmo e composição farmacêutica
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
MA63861A1 (fr) Composition pharmaceutique de virus non enveloppé
BR0111678A (pt) Composições medicinais contendo derivados de propenona
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
BR0009674A (pt) Composto, droga, e, uso de composto
Chaves et al. How proteolytic inhibitors interact with dentin on glass-fiber post luting over 6 months

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20201204

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7